Replies to post #180785 on NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

Returning to work after multimodal treatment in glioblastoma patients.

Article (PDF Available) in Neurosurgical FOCUS 44(6):E17 · June 2018

OBJECTIVE:
Although multimodal treatment for glioblastoma (GBM) has resulted in longer survival, uncertainties exist regarding health-related quality of life and functional performance. Employment represents a useful functional end point and an indicator of social reintegration. The authors evaluated the rate of patients resuming their employment and the factors related to work capacity.

Discussion:

“GBM diagnosis and treatment has a significant socio-professional impact, with only a minority of patients being able to continue or resume their previous employment.
In our cohort, of the 125 patients who were working before their diagnosis, only 18.8% went back to work, most on a part-time basis”

https://www.researchgate.net/publication/325512535_Returning_to_work_after_multimodal_treatment_in_glioblastoma_patients